Potential of GLP-1 in Diabetes Management
- 1 January 1996
- book chapter
- Published by Springer Nature
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoJournal of Clinical Endocrinology & Metabolism, 1995
- Glucagon‐like peptide 1: A potent glycogenic hormoneFEBS Letters, 1994
- Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.JCI Insight, 1994
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomyDigestive Diseases and Sciences, 1991
- Carboxypeptidase‐B‐like processing of the C‐terminus of glucagon‐like peptide‐2 in pig and human small intestineFEBS Letters, 1989
- Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.JCI Insight, 1987
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- Rat pancreas contains the proglucagon(64–69) fragment and arginine stimulates its releaseFEBS Letters, 1985
- Purification and chemical characterization of a glicentin-related pancreatic peptide (proglucagon fragment) from porcine pancreasBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982